Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
February 2022
in “
Cancers
”
The document reviewed literature on managing prostate cancer in individuals with high-risk germline mutations. It concluded that the quality of existing evidence was low, highlighting an urgent need for further research and the development of consensus guidelines to inform clinical practice for these patients.